Cargando…

2287. Recently Approved HEPLISAV-B(R) [Hepatitis B Vaccine (Recombinant), Adjuvanted] Shows a Higher Proportion of Subjects Achieving Seroprotection With a More Consistent Immune Response Compared With Engerix-B(R) [Hepatitis B Vaccine (Recombinant)] in Three Comparative Trials

BACKGROUND: HEPLISAV-B(®) [hepatitis B vaccine (recombinant), adjuvanted] uses a cytidine phospho-guanosine (CpG) oligonucleotide or “1018,” a Toll-like receptor 9 agonist, as an adjuvant. Engerix-B(®) [hepatitis B vaccine (recombinant)], as well as other hepatitis B vaccines, use alum. HEPLISAV-B,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyer, Randall N, Janssen, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254810/
http://dx.doi.org/10.1093/ofid/ofy210.1940

Ejemplares similares